A polipoprotein A-V (apoA-V) was discovered by comparative genome analysis and shown to function as a modulator of plasma triacylglycerol levels. 1 ApoA-V is a lowabundance plasma protein (25-400 ng/mL) that associates with very low-density lipoprotein (VLDL) and high-density lipoprotein. [2] [3] [4] It has been proposed that apoA-V modulates plasma triacylglycerol-rich lipoprotein metabolism by binding to glycosylphosphatidylinositol high-density lipoproteinbinding protein 1 (GPIHBP1), thereby promoting lipoprotein lipase (LPL)-mediated triacylglycerol hydrolysis. 5 Genome-wide association studies have identified singlenucleotide polymorphisms (SNPs) in APOA5 that correlate with elevated plasma triacylglycerol. 6 Kao et al 7 described a c.553G>T APOA5 SNP in a Taiwanese population that gives rise to a Cys for Gly substitution at position 185 of the preprotein, corresponding to residue 162 in mature, circulating apoA-V. This polymorphism introduces a second cysteine into apoA-V, with the other occurring at position 204. Minor allele frequency in control subjects is 0.042 compared with 0.27 (P<0.001) in subjects with hypertriglyceridemia. Serum triacylglycerol levels showed a gene dosage effect, corresponding to 92±38 mg/dL in G/G subjects, 107±35 mg/dL in G/T individuals, and 183 mg/dL in individuals with the T/T genotype (P=0.014). In another study, Pullinger et al 8 reported that the T-allele frequency was 4 times higher in Chinese subjects with hypertriglyceridemia compared with those with low triacylglycerol (15.1% versus 3.7%). Among those with hypertriglyceridemia, heterozygosity was associated with doubling of plasma triacylglycerol, whereas homozygotes manifest severe hypertriglyceridemia (mean triacylglycerol=2292±447 mg/dL). More recently, the c.553G>T SNP has been identified in subjects of European ancestry, 9,10 indicating worldwide occurrence.
Insofar as hypertriglyceridemia is an independent risk factor for coronary artery disease 11 and is a component of the metabolic syndrome, 12 there is great interest in understanding the molecular basis whereby APOA5 SNPs lead to elevated plasma triacylglycerol. 13 Indeed, given the frequency of the c.553G>T APOA5 SNP, it may be anticipated that millions of people worldwide are carriers. Dorfmeister et al 14 reported that G162C apoA-V forms multimers in vitro, although the bulk of the protein is monomeric. Binding studies with members of the low-density lipoprotein receptor family indicated that G162C apoA-V is functional, leading these authors to propose defective LPL activation as the underlying mechanism. In another study, Huang et al 15 investigated the effect of different amino-acid-substitution mutations at position 162 in apoA-V on its LPL activation properties, with the finding that Gly at this position is important in terms of LPL activation in vitro.
In a recent study, Sharma et al 16 reported that adeno-associated virus (AAV) 2/8-mediated gene transfer of wild-type (WT) apoA-V improved the hypertriglyceridemia phenotype of apoa5 (−/−) mice. In this study, it is demonstrated that gene transfer of G162C apoA-V results in a protein that forms disulfide-linked heterodimers with extraneous plasma proteins, resulting in an unusual plasma distribution pattern, defective lipoprotein binding, and compromised triacylglycerol-lowering activity.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

ApoA-V Expression After AAV2/8-Mediated Gene Transfer Into apoa5 (−/−) Mice
Previous gene transfer studies with AAV2/8 showed that the virus homes to liver tissue. 16 Consistent with this, gene amplification of cytomegalovirus promoter DNA in liver extracts from each of 8 apoa5 (−/−) mice transduced with AAV2/8-LacZ, AAV2/8-WT apoA-V, or AAV2/8-G162C apoA-V provided evidence of vector delivery to the target organ ( Figure 1A) . Whereas no apoA-V mRNA was detected in liver extracts of mice transduced with AAV2/8-LacZ, similar levels of apoA-V mRNA were present ( Figure 1B ) in liver extracts of mice injected with AAV2/8-WT apoA-V or AAV2/8-G162C apoA-V.
Effect of AAV2/8-G162C apoA-V on Plasma apoA-V and Triacylglycerol Levels
To assess relative plasma levels of WT-and G162C-apoA-V protein, blood was drawn each week for 4 weeks after gene transfer and immunoblot analysis were performed ( Figure 2A ). ApoA-V was detected in both groups after 1 week and increased in subsequent weeks, reaching a maximum at 4 weeks post transduction. From comparison of relative band intensities, it may be concluded that plasma concentrations of WT apoA-V and G162C apoA-V are in the same range. The triacylglycerol content of individual mouse plasma samples was measured as a function of time after gene transfer of AAV2/8-LacZ, AAV2/8-WT apoA-V, and AAV2/8-G162C apoA-V ( Figure 2B ). After injection with AAV2/8-LacZ, plasma triacylglycerol levels gradually increased, reaching 20% above baseline after 4 weeks. On the other hand, plasma triacylglycerol levels steadily declined in mice injected with AAV2/8-WT apoA-V. Indeed, after 4 weeks, plasma triacylglycerol levels were 69% lower than the corresponding values for AAV2/8-LacZ-transduced mice (P=0.0003). By contrast, plasma triacylglycerol levels in mice transduced with AAV2/8-G162C apoA-V remained relatively constant over time. As a result, at 4 weeks, triacylglycerol levels in these mice were 21% lower than those in AAV2/8-LacZ-transduced mice (P=0.32; not significant) and 50% higher (P=0.005) than those in AAV2/8-WT apoA-V-transduced mice. Thus, despite the fact that their corresponding mRNA and plasma protein concentrations are 
Lipid and apoA-V Distribution in Transduced Mouse Plasma
Four weeks after injection of AAV2/8-LacZ, AAV2/8-WT apoA-V, or AAV2/8-G162C apoA-V into apoa5 (−/−) mice, the animals were euthanized and blood was collected. Pooled plasma samples from each group were subjected to fast protein liquid chromatography to separate individual lipoprotein classes and the lipoprotein-free fraction. Lipid analysis confirmed that triacylglycerol lowering in mice transduced with WT apoA-V was substantial and confined to VLDL ( Figure 3A ). By contrast, gene transfer of AAV2/8-G162C apoA-V induced only a slight decline in VLDL triacylglycerol, when compared with AAV2/8-LacZ-injected mice. Cholesterol lowering in mice transduced with WT apoA-V was confined to VLDL ( Figure 3B ). SDS-PAGE immunoblot analysis of fractionated lipoproteins under reducing conditions revealed that virtually all WT apoA-V was recovered in association with lipoprotein particles, primarily VLDL followed by high-density lipoprotein ( Figure 3C ). By contrast, G162C apoA-V showed a different distribution pattern, with large amounts of this protein recovered in the lipoprotein-free fraction. Densitometry analysis indicated that >50% of G162C apoA-V was present in the lipoprotein-free fraction of plasma, when compared with <1% for WT apoA-V. To assess whether G162C apoA-V in the lipoprotein-free fraction of plasma may be the result of homo-or heterodisulfide bond formation via the Cys residue introduced by the c.553G>T SNP, SDS-PAGE immunoblot analysis was performed under nonreducing conditions ( Figure 3D ). Whereas all WT apoA-V, as well as that portion of G162C apoA-V recovered in lipoprotein fractions, migrated as a monomeric protein, G162C apoA-V recovered in the lipoprotein-free fraction displayed much slower electrophoretic mobility, with several discrete higher-molecular-weight bands present.
Characterization of G162C apoA-V in T/T Human Plasma
To evaluate the extent to which observations made in AAV2/8-G162C apoA-V-transduced apoa5 (−/−) mice recapitulate the physiological processes in humans harboring the c.553G>T SNP, pooled plasma from individuals homozygous for the variant (T/T) allele was subjected to density ultracentrifugation to obtain the lipoprotein-free bottom fraction. After dialysis, immunoprecipitation was performed with anti-apoA-V IgG. Precipitated proteins were subjected to nonreducing SDS-PAGE, transferred to polyvinylidene fluoride, and probed with α-apoA-V ( Figure 4 ). The data show that, as with plasma from apoa5 (−/−) mice transduced with G162C apoA-V ( Figure 3 ), T/T plasma possessed abundant apoA-V protein with slower electrophoretic mobility in the lipoprotein-free fraction. To assess whether some portion of apoA-V in T/T plasma is associated with the lipoprotein-rich top fraction, immunoblots for apoA-V were performed as described in Figure  I in the online-only Data Supplement. The data reveal that some apoA-V associates with lipoproteins and that high-molecularweight adducts are present. Unlike T/T results, the lipoproteinfree bottom fraction from pooled G/G plasma showed no apoA-V (data not shown). Based on these findings, studies designed to identify the binding partner(s) with which apoA-V interacts were performed with human plasma samples.
Identification of G162C apoA-V Interaction Partners in T/T Human Plasma
To identify proteins with which G162C apoA-V interacts in human plasma, immunoprecipitation and liquid chromatography/mass spectrometry analysis were performed. Using the positive staining region of a T/T plasma sample immunoblot as the guide, the corresponding low-mobility regions from a parallel gel were excised, digested with trypsin, and subjected to liquid chromatography/mass spectrometry. The sample from subjects homozygous for the T/T allele yielded numerous interacting protein candidates (Table) that were absent or detected at far lower levels in the G/G sample or a T/T plasma sample subjected to immunoprecipitation with beads lacking Ab. The relative abundance of proteins in each sample was approximated by calculating its contribution to a sum of the exponentially modified protein indices assigned to each sample component (mol %). 17 The generated mol % values were then compared across samples. Only proteins that demonstrated ≥4-fold higher relative abundance in the T/T sample versus controls (G/G plasma or T/T plasma subjected to immunoprecipitation with beads lacking Ab) were considered potential apoA-V-interacting partners. As expected, apoA-V was detected only in the T/T sample. Among the confidently identified proteins, which met the above acceptance criteria, were the extracellular matrix protein, fibronectin, kininogen-1 (a constituent of the blood coagulation system), and the immune-related proteins, complement C1q, Ig γ-2 chain C region, and complement factor B. Of note, relative abundances of all candidate proteins were either close to or lower than that of apoA-V itself (molar fraction=0.28%). In studies designed to obtain independent verification of the mass spectrometry results presented, an antibody directed against one of the candidate proteins (apoE) was used to probe T/T and G/G plasma sample apoA-V immunoprecipitates ( Figure II in the online-only Data Supplement). The data reveal apoE immunoreactivity only in the T/T plasma lipoprotein-rich fraction.
Discussion
ApoA-V is a member of the class of exchangeable apolipoproteins that is synthesized only in liver. 1, 18 After signal sequence cleavage, mature apoA-V is secreted into plasma, where it associates with plasma lipoproteins, particularly VLDL and high-density lipoprotein. 3 A unique aspect of apoA-V is a low abundance in plasma (between 25 and 400 ng/mL). Despite this low concentration, genome-wide association studies have consistently identified APOA5 as a risk factor for dyslipidemia and cardiovascular disease. Moreover, population studies have identified SNPs in APOA5 that correlate with elevated plasma triacylglycerol. Among these, the c.553G>T SNP (rs2075291) has attracted attention because of its common occurrence among those of East Asian ancestry and strong association with increased triacylglycerol levels.
Vaessen et al 19 evaluated the triacylglycerol-lowering activity of WT human apoA-V versus G162C apoA-V using adenovirus-mediated gene transfer in C57Bl/6 mice. In their study, at viral doses that increase apoA-V levels ≈50to 100-fold over those present in normal human plasma, both WT apoA-V and G162C apoA-V exerted a plasma triacylglycerol-lowering effect. No differences in other plasma parameters, including free fatty acids and glycerol concentrations or postheparin LPL activity, were noted. The authors concluded that, despite its strong correlation with hypertriglyceridemia, G162C apoA-V is functionally able to reduce plasma triacylglycerol levels in mice. Two problems associated with this study include (1) extreme overexpression of apoA-V and (2) the use of WT mice that express endogenous apoA-V. The former problem results in supraphysiological levels of apoA-V that may override normal homeostatic processes. The second problem is that plasma triacylglycerol levels in the recipient mice are low to begin with. Thus, any triacylglycerol-lowering effect caused by transduced apoA-V will be relatively small. In this study, the apoa5 (−/−) mice used have hypertriglyceridemia, permitting evaluation of possible mechanisms underlying the correlation between the c.553G>T APOA5 SNP and elevated plasma triacylglycerol. Unlike the findings of Vaessen et al, 19 we found that when expressed in apoa5 (−/−) mice, apoA-V levels resemble that of human plasma and G162C apoA-V displays defective triacylglycerol-lowering activity compared with WT apoA-V.
The results suggest that alterations in the plasma distribution of G162C apoA-V, when compared with WT apoA-V, may account for the observed loss of function. Whereas lipoprotein association is considered an absolute requirement for manifestation of apoA-V triacylglycerol-lowering activity, 4 a large proportion of G162C apoA-V in plasma of transduced mice was recovered in the lipoprotein-free fraction. When associated with triacylglycerol-rich lipoproteins, WT apoA-V directs these particles to GPIHBP1 via a specific binding interaction. 20 A positively charged sequence motif, located between residues 186 to 227 in apoA-V, mediates interaction with the highly acidic N-terminal segment of GPIHBP1, effectively sequestering lipoproteins at the endothelial cell surface. Insofar as LPL also binds GPIHBP1, 21 current models propose that apoA-V indirectly activates lipolysis by promoting triacylglycerol-rich lipoprotein binding to sites at the endothelial cell surface (ie, GPIHBP1) where LPL resides. 22 Recently, Gonzales et al 23 reported that apoA-V also directs lipoproteins to proteoglycans on the surface of hepatocytes, thereby promoting whole-particle uptake by receptor-mediated endocytosis, a complementary means whereby triacylglycerol lowering can be achieved.
An obvious question is why does a large portion of G162C apoA-V distribute to the lipoprotein-free fraction of plasma? A clue to the underlying reason emerged from studies by Dorfmeister et al 14 who showed that G162C apoA-V forms disulfide-linked dimers in vitro. In a similar manner, in this study, apoA-V recovered in the lipoprotein-free fraction displays altered electrophoretic mobility under nonreducing conditions. Taken together, the *Proteins were identified from specified human plasma samples after immunocapture with anti-apolipoprotein A-V IgG-or controldirect-immunoprecipitation beads. Immunoprecipitated proteins were separated by nonreducing SDS-PAGE, and excised gel slices were digested with trypsin before liquid chromatography/mass spectrometry, as described in Materials and Methods section.
†Protein score and molar fraction were calculated as described in Materials and Methods section. Protein score is the sum of the highest ions score for each distinct peptide sequence. Molar fraction (mol %) for each protein represents a contribution of its exponentially modified protein indices (emPAI) value to the total emPAI values of all proteins identified in the sample. emPAI relies on an assumption that the extent to which the theoretically observable peptides derived from a protein identified (observed) in the analysis directly correlates with the relative abundance of a protein in a sample. emPAI values were estimated by the Mascot search engine using protein molecular mass, the average amino acid composition of the database, and enzyme specificity to derive many theoretically observable peptides.
‡Molar ratio values are indicated when a given protein was also detected in G/G plasma or T/T plasma immunoprecipitated with beads lacking Ab. Only proteins with either ratio >4 are shown.
§Fibronectin peptides cover sequence: G/G plasma 1435 to 2176; T/T plasma, 370 to 2356.
evidence indicates that the c.553G>T polymorphism introduces a free cysteine sulfhydryl into apoA-V that is available for homo-or heterodisulfide bond formation. It seems that, on secretion from hepatocytes, G162C apoA-V has 2 possible, yet mutually exclusive, fates. On one hand, G162C apoA-V may associate with lipoproteins in a functionally productive manner; on the other hand, it may form a heterodisulfide bond with seemingly unrelated plasma proteins. Previous studies have shown that, although 100% of WT apoA-V associates with lipoproteins, it is not secreted from cells in complex with nascent apoB-containing lipoproteins. 24 Thus, it is envisaged that apoA-V rapidly transitions from a lipid-free or lipid-poor state to a lipoprotein-associated state after secretion from hepatocytes. Formation of a disulfide bond between G162C apoA-V and extraneous plasma proteins seems to preclude lipoprotein binding by G162C apoA-V, rendering it ineffective in terms of triacylglycerol lowering. The finding that, in transduced mice, the fraction of the G162C apoA-V pool recovered in association with lipoproteins does not display retarded electrophoretic mobility under nonreducing conditions suggests that competition between these 2 fates occurs ( Figure 5 ). At present it is not known whether prior association with lipoproteins affects disulfide bond formation or if disulfide bond formation leads to dissociation of apoA-V from lipoproteins. It is also possible that newly secreted lipid-poor G162C apoA-V is prevented from lipoprotein association by prior disulfide bond-linked heterodimer formation.
Regardless of the sequence of events, it is evident that introduction of this free cysteine leads to the appearance of a lipoprotein-free, nonfunctional pool of apoA-V. At the same time, it may be considered that the residual pool of lipoprotein-bound G162C apoA-V in plasma of transduced apoa5 (−/−) mice is responsible for the ≈20% lowering of plasma triacylglycerol versus LacZ transduced mice after 4 weeks. Whether lipoprotein-associated G162C apoA-V is equivalent to WT apoA-V in terms of GPIHBP1 binding remains to be determined. Nonreducing SDS-PAGE immunoblot analysis of plasma from apoa5 (−/−) mice transduced with G162C apoA-V provided evidence for unique apoA-V positive bands with lower electrophoretic mobility than monomeric apoA-V. On the basis of immunoprecipitation experiments with human plasma samples using anti-apoA-V IgG-derivatized beads and liquid chromatography/mass spectrometry analyses, 13 unique candidate G162C apoA-V-interacting proteins were identified. Whereas each of these proteins possess cysteine residues and hence are physically capable of forming a disulfide bond with G162C apoA-V, 4 candidates identified may be regarded as intracellular proteins (bleomycin hydrolase, protein S100-A7, caspase-14, and hemoglobin subunit β). A candidate protein detected at much higher levels (protein score 942) than other proteins identified was fibronectin. Fibronectin is a relatively abundant (≈300 μg/mL) plasma glycoprotein that also functions as an extracellular matrix component. Plasma fibronectin is a cysteine-rich heparin-binding protein that, on deposition at sites of injury, forms clots that protect the underlying tissue. Among the many proteins with which fibronectin interacts is lipoprotein(a), providing a potential connection to lipoprotein metabolism. 25 Another candidate interaction partner is kininogen-1, a component of the blood coagulation cascade that possesses heparan sulfate proteoglycan-binding activity. 26 Unlike other proteins identified, this candidate was also detected in both control samples. Despite this, inclusion criteria were met for a specific G162C apoA-V-binding interaction (Table) . Other proteins identified as G162C apoA-V-interacting partners are complement C1q subcomponent subunit B, Ig γ2-C, and complement factor B. Although it was identified on the basis of a single peptide, a candidate interacting partner that has a well-known connection to lipoprotein metabolism is apoE. Because mouse apoE lacks cysteine, it is unlikely to be a binding partner for G162C apoA-V. Consistent with the fact that human apoE3 possesses a free sulfhydryl, it is not surprising that immunoblot analysis confirmed that it forms an adduct with G162C apoA-V, but not with WT apoA-V. Interestingly, apoE has previously been reported to form a disulfide bond with apoA-II. 27 In considering the range of proteins identified by liquid chromatography/mass spectrometry as potential interaction partners with G162C apoA-V, no specific connection is readily apparent. Indeed, whereas certain candidate binding partners identified are relatively abundant plasma proteins, others are considered intracellular proteins such that, if present, their plasma concentration would be expected to be too low. It is conceivable that one or more of the proteins identified does not actually interact with G162C apoA-V but rather, it is detected by the fact that it interacts with another protein on the list with which G162C apoA-V does interact. Furthermore, based on the fact that the most abundant proteins in plasma were not detected, it is unlikely that G162C apoA-V interactions are entirely random. In considering this, it is noteworthy that several candidates share with apoA-V 28 an ability to bind sulfated glycosaminoglycans (ie, fibronectin, kininogen-1, zinc α-2 glycoprotein, complement factor B, histidine-rich glycoprotein, and apoE). Thus, it is conceivable that the initial contact between interacting partners is facilitated by this shared property, and once a disulfide bond forms, the functional ability of apoA-V is compromised.
In summary, we conclude that the rs2075291 APOA5 SNP introduces a free sulfhydryl that forms disulfide bonds with various proteins it encounters in plasma. This alternate fate affects the lipoprotein-binding properties of G162C apoA-V, thereby abrogating its ability to modulate plasma triacylglycerol levels. Given the correlation between the c.553G>T APOA5 SNP and Figure 5 . Model depicting opposing fates of G162C apolipoprotein A-V (apoA-V) in plasma. Left, On secretion from hepatocytes, wild-type (WT) apoA-V associates with very lowdensity lipoprotein (VLDL) and high-density lipoprotein (HDL) and remains 100% lipoprotein bound. Right, In addition to lipoprotein association, G162C apoA-V forms disulfide bonds with extraneous plasma proteins, thereby abrogating its lipoprotein interaction capability (depicted by the X). As such, heterodisulfide-bonded G162C apoA-V constitutes a nonfunctional pool of apoA-V in terms of triacylglycerol modulation. hypertriglyceridemia in human subjects, the strong correlation between hypertriglyceridemia and dyslipidemic disease, and the apparent worldwide prevalence of this SNP, apoA-V gene therapy represents a potential disease prevention strategy.
